

# House Oversight Committee calls on FDA to regulate CBD

BY NATALIE FERTIG | 04/18/2023 10:57 AM EDT

The House Committee on Oversight and Accountability [will investigate](#) the Food and Drug Administration's continued lack of regulations for CBD products.

Cannabis with less than 0.3 percent THC — legally known as hemp — was legalized by the 2018 farm bill. Nearly five years later, the FDA has still not issued regulations for CBD products — the most popular compound in hemp.

Oversight Chair [James Comer](#) (R) is from Kentucky, which has become a center of the struggling industry. Hemp companies and trade groups have been calling on the FDA for years to regulate CBD as a dietary supplement — something the agency [announced earlier this year it would not do](#).

Comer said in a statement the committee will "seek documents and information to enable oversight of the FDA's actions" related to CBD.

"FDA's claim of a lack of a regulatory pathway is not only an insufficient rationale for inaction, but it is directly affecting the welfare of the American public," Comer added. "The good faith actors in the industry are unable to enter the market and provide people with helpful products because they are currently not distinguished under the FDA from the intoxicating products containing Delta-8."

**The [letter to the FDA](#) asked for specific documentation**, including any communications and drafts related to the Jan. 26 announcement on CBD, documents related to the FDA's assessment of the framework that makes regulating CBD difficult, and any scientific data the agency has related to safety of CBD for consumption.

The committee wants to receive those documents by May 1.

[View this article online.](#)

You received this POLITICO Pro content because your customized settings include: *Marijuana and Hemp*. You can customize all of your alert criteria on your [settings page](#).

This email alert has been sent for the exclusive use of POLITICO Pro subscriber, [jmiller@fbtlaw.com](mailto:jmiller@fbtlaw.com). Forwarding or reproducing the alert without the express, written permission of POLITICO Pro is a violation of copyright law and the POLITICO Pro subscription agreement.

Copyright © 2023 by POLITICO LLC. To subscribe to Pro, please go to [politicopro.com](https://politicopro.com).

This email was sent to [jmiller@fbtlaw.com](mailto:jmiller@fbtlaw.com) by:

POLITICO, LLC

[1000 Wilson Blvd.](#)

Arlington, VA 22209

USA